November 2, 2018 07:52 AM EDT

Illumina forks out $1.2B to buy rival Pacific Biosciences, placing long and short-read DNA tech under the same roof

ENDPOINTS

Illumina $ILMN is consolidating its pole position in the gene sequencing market by acquiring smaller rival Pacific Biosciences $PACB in a $1.2 billion

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Illumina forks out $1.2B to buy rival Pacific Biosciences, placing long and short-read DNA tech under the same roof

ENDPOINTS

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?

Il­lu­mi­na forks out $1.2B to buy ri­val Pa­cif­ic Bio­sciences, plac­ing long and short-read DNA tech un­der the same roof

ENDPOINTS

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Illumina forks out $1.2B to buy rival Pacific Biosciences, placing long and short-read DNA tech under the same roof

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?